Columbia University

Technology Ventures

Featured Funding Opportunities

In support of its mission to facilitate the transfer of inventions from academic research labs to the market, CTV publicizes funding opportunities that may be relevant to Columbia inventors as they conduct research and develop new technologies. For additional lists of funding opportunities, refer to these resources:

For further assistance with grant applications, see CTV's collection of IP and Entrepreneurship Language for Grant Applications.

Past Funding Opportunities

Thursday, April 15, 2021 - 5:00pm

The RTW Charitable Foundation’s mission is to improve opportunities for all people to live healthier, longer lives by identifying unmet needs and impacting research and patients directly.  

Thursday, February 25, 2021 - 5:00pm

CSL’s Research Acceleration Initiative aims to fast-track discovery of innovative biotherapies through partnerships between CSL and global research organizations.

The 2021 Research Acceleration Initiative will focus on research projects that span a CSL Therapeutic Area and a Focus Area, and that are amenable to or include a Modality listed below:

Therapeutic Area (emphasis on rare disease):

  • Immunology
  • Hematology
  • Respiratory
  • Cardiovascular/Metabolic
  • Transplant

Focus Areas:

Tuesday, February 23, 2021 - 12:00am

Columbia University, New York University, and Takeda Pharmaceuticals have formed a collaborative research alliance to initiate and advance gastroenterology (GI) research programs with high potential to impact the development of new therapeutics for patients with GI disorders. This cycle of the Alliance has a particular thematic focus on GI Inflammation and neuroinflammation; motility and modulating enteric nervous system biology; and liver.

Friday, February 5, 2021 - 5:00pm

Bristol Myers Squibb seeks proposals on topics designed to address questions developed by its Immuno-Oncology and Cell Therapy (IOCT) Thematic Research Center.

Areas of interest:

  • Approaches to normalize the tumor vasculature to improve cell therapy/T cell engagers/NK cell engager therapies
  • Novel technology which can support cell therapy target identification for solid tumors
  • Targeting T cell metabolism pathways to improve T cell fitness for cell therapy in vivo

RFP guidelines:

Monday, December 14, 2020 - 5:00pm

Why did Atomwise create this award?
The goal of this program is to broaden the pool of scientists pursuing drug discovery. To advance this goal, Atomwise will award researchers with a customized virtual screen using cutting-edge Artificial Intelligence (AI) technology, approximately 72 chemical compounds for physical screening, and technical support from medicinal chemists and computational biologists.

Friday, November 13, 2020 - 5:00pm



Emerson Collective seeks to fund collaborative clinical research focused on populations with unequal burdens of colorectal cancer (CRC) by exploring the association between molecular characteristics such as tumor mutation and clinical characteristics such as disease stage, recurrence rate, and overall survival. 

Saturday, October 31, 2020 - 5:00pm



Cyclica is an AI-based drug discovery company that has developed a structure-based, AI-augmented in silico drug discovery platform. CAPP is an opportunity for academic investigators to apply for in-kind access to Cyclica’s drug development platforms. The program offers two types of awards: 

Ligand Design Award: to generate novel compounds for your target of interest